We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 378.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMIDH
RNS Number : 6868N
Immunodiagnostic Systems Hldgs PLC
10 August 2017
Immunodiagnostic Systems Holdings plc.
10 August 2017
Launch of IDS-iSYS Free Testosterone assay - new assay in the IDS fertility portfolio
Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has today launched the IDS-iSYS Free Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.
The launch of the IDS-iSYS Free Testosterone assay is the third product released as part of the emerging fertility (steroid hormones) portfolio.
The IDS-iSYS Free Testosterone assay quantitatively measures a patient's Free Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens). Measurement of free testosterone may provide additional information in patients whereby the measured total testosterone levels are low.
As the first fully automated solution, the IDS-iSYS Free Testosterone assay is a valuable addition to the developing IDS fertility portfolio; allowing laboratories to benefit from reduced time to first result for measurement of patient samples.
The global market for testosterone testing is valued at around $110 million per year.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Regis Duval, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUQARUPMGPU
(END) Dow Jones Newswires
August 10, 2017 09:00 ET (13:00 GMT)
1 Year Immunodiagnostic Systems Chart |
1 Month Immunodiagnostic Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
